

analyte thereof related to said disease state; and

means for determining binding between said biochemical material and said biomolecule;

whereby at least one analysis to determine a presence of a marker, analyte thereof, or a

biochemical material specific thereto, is carried out on a sample.

A3
Cont'd

Claim 29. Polyclonal antibodies produced against a marker sequence ID selected from the group having a sequence identified as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or at least one analyte thereof in at least one animal host.

Claim 30. An antibody that specifically binds a biopolymer including a marker selected from the group having a sequence identified as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or at least one analyte thereof.

A5

Claim 33. A process for identifying therapeutic avenues related to a disease state comprising:

conducting an analysis as provided by the kit of claim 18; and

interacting with a biopolymer selected from the group having a sequence identified as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or at least one analyte thereof;

whereby therapeutic avenues are developed.